Polley, Mei-Yin C.
Leon-Ferre, Roberto A.
Leung, Samuel
Cheng, Angela
Gao, Dongxia
Sinnwell, Jason
Liu, Heshan
Hillman, David W.
Eyman-Casey, Abraham
Gilbert, Judith A.
Negron, Vivian
Boughey, Judy C.
Liu, Minetta C.
Ingle, James N.
Kalari, Krishna
Couch, Fergus
Carter, Jodi M.
Visscher, Daniel W.
Nielsen, Torsten O.
Goetz, Matthew P.
Funding for this research was provided by:
National Cancer Institute (P50 CA116201)
Breast Cancer Research Foundation
Article History
Received: 30 July 2020
Accepted: 16 November 2020
First Online: 3 January 2021
Compliance with ethical standards
:
: Dr. Torsten O. Nielsen holds a proprietary interest in the Prosigna breast cancer assay through Bioclassifier LLC, licensed to Veracyte, Inc. Dr. Goetz reports personal fees from Genomic Health, consulting fees from Lilly, Biovica, Novartis, Sermonix, Context Pharm, Pfizer, Biotheranostics, and grants from Pfizer, Lilly, and Sermonix. Other authors declare that they have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: The need for obtaining informed consent was waived by the institutional review board, given that this study was retrospective and non-interventional.